<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) is the most important cause of mortality in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and is preceded by <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Flow-mediated dilation (FMD) is a noninvasive technique for measuring <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We aimed to determine the effect of long-term <z:chebi fb="0" ids="35664">statin</z:chebi> therapy versus placebo on FMD in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> without manifest <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: A randomized, placebo-controlled, double-blind trial was performed with 250 type 2 diabetic patients </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were given 0.4 mg cerivastatin or placebo daily </plain></SENT>
<SENT sid="5" pm="."><plain>In August 2001, when cerivastatin was withdrawn from the market, the 0.4 mg cerivastatin was replaced by 20 mg <z:chebi fb="0" ids="9150">simvastatin</z:chebi>, without deblinding the study </plain></SENT>
<SENT sid="6" pm="."><plain>The primary end point was the change in FMD, measured by B-mode ultrasound, after 2 years </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Determinants of baseline FMD were <z:mp ids='MP_0002055'>diabetes</z:mp> duration, common carotid intima-media thickness, and brachial artery diameter </plain></SENT>
<SENT sid="8" pm="."><plain>FMD at baseline was 1.51% in the placebo group and 1.66% in the <z:chebi fb="0" ids="35664">statin</z:chebi> group and did not change significantly after 2 years </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The 2-year <z:chebi fb="0" ids="35664">statin</z:chebi> therapy had no effect on FMD in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="35664">Statin</z:chebi>-induced improvement of cardiovascular risk in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> may be mediated through mechanisms other than increased nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> availability </plain></SENT>
</text></document>